Related Experiment Video
Updated: Aug 29, 2026
Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure
Published on: May 27, 2022
Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients
Eric Dannaoui1, Joseph Meletiadis1, Anna-Maria Tortorano1
1Laboratoire de Parasitologie, Mycologie Médicale et Pathologie Exotique, Université Claude Bernard Lyon I, 69373 Lyon Cedex 08, France 2Department of Medical Microbiology, University Medical Center St Radboud, 6500 HB Nijmegen, The Netherlands 3Istituto di Igiene e Medicina Preventiva, Università degli Studi -IRCCS Ospedale Maggiore, 20122 Milan, Italy 4Scientific Institute of Public Health, B-1050 Brussels, Belgium 5Laboratoire Interactions Cellulaires Parasite-Hôte, Université Joseph Fourier Grenoble I, 38706 Grenoble Cedex, France 6European Research Group on Biotypes and Genotypes of Aspergillus fumigatus.
Abstract:
Two-hundred sequential Aspergillus fumigatus isolates recovered from 26 immunocompromised patients with invasive aspergillosis or bronchial colonization were tested for their in vitro susceptibility to posaconazole, itraconazole, voriconazole, terbinafine and amphotericin B. Twenty-one patients were treated with amphotericin B and/or itraconazole. Antifungal susceptibilities of the isolates recovered before treatment were not significantly different from those of isolates recovered after the onset of antifungal therapy. The highest MICs were 0.125, 0.5, 0.5, 1 and 1 microg ml(-1) for posaconazole, itraconazole, voriconazole, terbinafine and amphotericin B, respectively. It is concluded that the emergence of resistance in A. fumigatus during antifungal therapy with amphotericin B or itraconazole is an uncommon phenomenon.